BioCentury
ARTICLE | Company News

AZ, UPMC in value-based agreement for Brilinta

January 28, 2019 10:22 PM UTC

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization for heart attack or unstable angina. The contract includes a dual-sided financial risk component in which clinical outcomes will determine the level of shared costs between the partners.

UPMC Health Plan said Brilinta will be reduced to about $9 from $47, offering patients the acute coronary syndrome (ACS) drug at a generic tier co-pay. The insurer added that the contract will help in "removing cost as a barrier to medication adherence."...